XM does not provide services to residents of the United States of America.
L
L

Lonza

News

AB Dynamics, Etteplan, Wise

EUROPE RESEARCH ROUNDUP-AB Dynamics, Etteplan, Wise June 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AB Dynamics, Etteplan and Wise, on Friday. HIGHLIGHTS * AB Dynamics Plc ABDP.L : Berenberg re-initiates coverage With Buy rating; PT 2,620p * Crest Nicholson CRST.L : Barclays cuts target price to 230p from 258p * Etteplan Oyj ETTE.HE : Evli Research raises to buy from hold * Halma HLMA.L : Barclays raises target price to 284
B
C
E
H
H
J
L
O
O
P
R
S
S
T
U
V
V
Z
H
A
R

Asmi, Beiersdorf, SSE

EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Asmi, Beiersdorf and SSE, on Friday. HIGHLIGHTS * Arcadis NV ARDS.AS : KBC Securities raises to accumulate from buy * Asmi ASMI.AS : Berenberg raises target price to EUR 720 from EUR 640 * Beiersdorf BEIG.DE : HSBC raises target price to EUR 158 from EUR 152 * Nibe Industrier AB NIBEB.ST : HSBC cuts to hold from buy * SSE SSE.L : HS
A
B
B
C
D
E
E
I
J
L
L
S
W

Asmi, Beiersdorf, SSE

CORRECTED-EUROPE RESEARCH ROUNDUP-Asmi, Beiersdorf, SSE Corrects Greenyard NV entry to say KBC Securities raises target price to EUR 9.5 from EUR 8.5 (not 6.30) and Arcadis NV entry to say KBC Securities cuts (not raises) to 'accumulate' from 'buy'; raises target price to EUR 66 from EUR 61 (not 61.7 June 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Asmi, Beiersdorf and SSE, on Friday.
A
B
B
B
C
D
D
E
E
I
J
K
L
L
P
R
S
V
V
V
W
P
S

Swiss pharma supplier Lonza reports softer Q1 but confirms outlook

UPDATE 1-Swiss pharma supplier Lonza reports softer Q1 but confirms outlook Adds outlook in paragraph 1, info about Biosecure Act in paragraph 5-6, CFO quote in paragraph 7 By Chiara Holzhaeuser and Tristan Veyet May 14 (Reuters) - Swiss pharmaceutical supplier Lonza LONN.S reported a "softer Q1" on Tuesday, while confirming its 2024 outlook, saying its lacklustre performance was mainly due to the phasing of commercial batches and a weaker start at its bioscience business.
B
L

Swiss pharma supplier Lonza flags signs of recovery in biotech funding

Swiss pharma supplier Lonza flags signs of recovery in biotech funding May 14 (Reuters) - Swiss pharmaceutical supplier Lonza LONN.S confirmed its 2024 outlook on Tuesday, flagging early signs of recovery in biotech funding even as clinical demand in its biologics division remained soft in the first quarter. It said commercial performance was positive across its biologics, small molecules, and cell & gene businesses in the quarter, while development in its capsules & health ingredients unit was
B
L

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.